<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Arthritis Res. Ther</journal-id><journal-title-group><journal-title>Arthritis Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28728606</article-id><article-id pub-id-type="pmc">5520291</article-id><article-id pub-id-type="publisher-id">1377</article-id><article-id pub-id-type="doi">10.1186/s13075-017-1377-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Levels of serum biomarkers from a two-year multicentre trial are associated with treatment response on knee osteoarthritis cartilage loss as assessed by magnetic resonance imaging: an exploratory study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Martel-Pelletier</surname><given-names>Johanne</given-names></name><address><email>jm@martelpelletier.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Raynauld</surname><given-names>Jean-Pierre</given-names></name><address><email>jp.raynauld@videotron.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mineau</surname><given-names>Fran&#x000e7;ois</given-names></name><address><email>fmineau@arthrolab.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Abram</surname><given-names>Fran&#x000e7;ois</given-names></name><address><email>fabram@arthrovision.biz</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Paiement</surname><given-names>Patrice</given-names></name><address><email>ppaiement@arthrolab.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Delorme</surname><given-names>Philippe</given-names></name><address><email>pdelorme@arthrolab.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Pelletier</surname><given-names>Jean-Pierre</given-names></name><address><email>dr@jppelletier.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0743 2111</institution-id><institution-id institution-id-type="GRID">grid.410559.c</institution-id><institution>Osteoarthritis Research Unit, </institution><institution>University of Montreal Hospital Research Centre (CRCHUM), </institution></institution-wrap>900 Saint-Denis, Suite R11.412, Montreal, Quebec H2X 0A9 Canada </aff><aff id="Aff2"><label>2</label>Medical Imaging Research &#x00026; Development, ArthroLab Inc, Montreal, Quebec Canada </aff><aff id="Aff3"><label>3</label>ArthroLab Inc, Montreal, Quebec Canada </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>19</volume><elocation-id>169</elocation-id><history><date date-type="received"><day>5</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>27</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">There is an obvious need to identify biomarkers that could predict patient response to an osteoarthritis (OA) treatment. This post hoc study explored in a 2-year randomized controlled trial in patients with knee OA, the likelihood of some serum biomarkers to be associated with a better response to chondroitin sulfate in reducing cartilage volume loss.</p></sec><sec><title>Methods</title><p id="Par2">Eight biomarkers were studied: hyaluronic acid (HA), C reactive protein (CRP), adipsin, leptin, N-terminal propeptide of collagen II&#x003b1; (PIIANP), C-terminal crosslinked telopeptide of type I collagen (CTX-1), matrix metalloproteinase-1 (MMP-1), and MMP-3. Patients were treated with chondroitin sulfate (1200&#x000a0;mg/day; <italic>n</italic>&#x02009;=&#x02009;57) or celecoxib (200&#x000a0;mg/day; <italic>n</italic>&#x02009;=&#x02009;62). Serum biomarkers were measured at baseline. The cartilage volume at baseline and its loss at 2&#x000a0;years were assessed by quantitative magnetic resonance imaging (MRI). Statistical analysis included analysis of covariance.</p></sec><sec><title>Results</title><p id="Par3">As data from the original MOSAIC trial showed no differences in cartilage volume and loss in the lateral compartment of the knee joint between the two treatment groups in any comparison, only the medial compartment and its subregions were studied. Stratification according to the median biomarker levels was used to discriminate treatment effect. In patients with levels of biomarkers of inflammation (HA, leptin and adipsin) lower than the median, those treated with chondroitin sulfate demonstrated less cartilage volume loss in the medial compartment, condyle, and plateau (<italic>p</italic>&#x02009;&#x02264;&#x02009;0.047). In contrast, patients treated with chondroitin sulfate with higher levels of MMP-1 and MMP-3, biomarkers of cartilage catabolism, had less cartilage volume loss in the medial compartment, condyle, and plateau (<italic>p</italic>&#x02009;&#x02264;&#x02009;0.050). Patients with higher levels of PIIANP and CTX-1, biomarkers related to collagen anabolism and bone catabolism, respectively, had reduced cartilage volume loss in the medial condyle (<italic>p</italic>&#x02009;&#x02264;&#x02009;0.026) in the chondroitin sulfate group.</p></sec><sec><title>Conclusion</title><p id="Par4">This study is suggestive of a potentially greater response to chondroitin sulfate treatment on cartilage volume loss in patients with knee OA with low level of inflammation and/or greater level of cartilage catabolism.</p></sec><sec><title>Trial registration</title><p id="Par5">This is a post hoc study. Original trial registration: ClinicalTrials.gov, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01354145?term=NCT01354145&#x00026;rank=1">NCT01354145</ext-link>. Registered on 13 May 2011.&#x000a0;</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13075-017-1377-y) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Knee</kwd><kwd>Osteoarthritis</kwd><kwd>Biomarkers</kwd><kwd>Clinical trial</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p id="Par23">Osteoarthritis (OA) is one of the most highly prevalent joint diseases characterized by progressive articular structural changes and cartilage degradation. This disease represents an increasing burden from a medical, social and economic point of view, as it affects the majority of people in the second half of their lifespan, having a significant negative impact on quality of life. The primary etiological factors may be numerous; hence, in the majority of patients the disease is considered to be idiopathic. At present, pharmacologic therapies only reduce symptoms, and they have adverse events. For this reason, attention has been focused on the investigation and development of new types of drugs that in addition to improving the clinical symptoms of OA and having better safety profiles can also decrease cartilage volume loss.</p><p id="Par24">One such product is chondroitin sulfate, which is a sulfated glycosaminoglycan that has been shown to play a role not only in the metabolism of the proteoglycans (a major macromolecule in the cartilage), but also in OA joint tissues and cells, to improve the anabolic/catabolic balance of the extracellular cartilage matrix, and to reduce some pro-inflammatory and catabolic factors and the resorptive properties of subchondral bone osteoblasts [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. In addition to its ability to reduce OA symptoms, similar to that of non-steroidal anti-inflammatory drugs (NSAIDs) [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], in clinical trials and studies [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>] it has also been shown to decrease cartilage volume loss as assessed by quantitative magnetic resonance imaging (qMRI). However, as mentioned in the original trial publication [<xref ref-type="bibr" rid="CR6">6</xref>], although it has been recommended in some guidelines [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], a general consensus has not been reached on the use of chondroitin sulfate [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>], due in part to the unavailability of prescription-quality products, indicated for use in OA, which have been evaluated by the US Food and Drug Administration (FDA) [<xref ref-type="bibr" rid="CR12">12</xref>]. Over the years, several studies have looked into identifying biomarkers with predictive value to assess the risk of OA progression, particularly in patients with knee OA (see reviews [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]). A number of such biomarkers have been identified, predominantly in observational patient cohort studies, yet none has qualified for use in clinical practice for the follow up of patients with knee OA [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. There is an obvious need to identify prognostic biomarkers, but an even greater need to identify biomarkers that could predict patient response to potential disease-modifying OA drug treatments [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par25">Recently, the Osteoarthritis Research Society International-FDA (OARSI-FDA) Biomarkers Group identified twelve distinct biochemical biomarkers of bone and cartilage turnover that could be of interest and included in the BIPEDS classification system [<xref ref-type="bibr" rid="CR17">17</xref>]. This group further looked at the predictive validity of eighteen biomarkers as OA-related predictors of radiographic and persistent pain progression [<xref ref-type="bibr" rid="CR18">18</xref>]. They identified nine such biomarkers that were individually able to predict clinically relevant progression over 48&#x000a0;months; eight catabolic and one anabolic biomarker.</p><p id="Par26">Most studies assessing biomarkers in relation to articular changes have used radiographic parameters, a technology that is not sensitive for the validation of biomarkers [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Converging data argue for the use of qMRI, another imaging technology that may assist in delineating the predictive value of biomarkers with regard to OA joint structural changes [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. A few trials have used this technology to identify biomarkers that would be of value in predicting drug efficacy in cartilage volume loss and clinical outcomes such as total knee replacement [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par27">The present study aimed to explore whether biomarkers could identify patients with knee OA most likely to benefit from a chondroitin sulfate treatment, a commonly used treatment for knee OA. The information gathered from the present study could be very useful in the context of personalized medicine, as targeting responders would reduce the cost of treatment for OA patients and, importantly, improve patient benefits.</p><p id="Par28">Using the knee OA patient cohort from a phase III clinical trial [<xref ref-type="bibr" rid="CR6">6</xref>], eight serum biomarkers (C reactive protein (CRP), hyaluronic acid (HA), leptin, adipsin, matrix metalloproteinase-1 (MMP-1), MMP-3, N-terminal propeptide of collagen II&#x003b1; (PIIANP) and C-terminal crosslinked telopeptide of type I collagen (CTX-1)) were assessed for their predictive value in determining the evolution of changes in cartilage in OA over a 2-year period by qMRI, and in relation to the effect of chondroitin sulfate treatment on cartilage volume loss. The rationale behind the selection of biomarkers was to use those that are representative of the most important pathways related to OA progression: inflammation (CRP, HA, leptin, and adipsin), cartilage catabolism (MMP-1, MMP-3) and anabolism (PIIANP), and bone remodeling (CTX-1), which have been found promising [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. We reasoned that the biomarkers chosen for the study covered a broad range of pathways including the major pathological pathways of OA and were therefore likely to provide new information about biomarkers that could be associated with a treatment effect on cartilage volume loss.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Patients and treatments</title><p id="Par29">This post hoc study used the patient cohort from a 2-year phase-III comparative, double-blind clinical trial (ClinicalTrials.gov Identifier NCT01354145) [<xref ref-type="bibr" rid="CR6">6</xref>]. In brief, patients with symptomatic knee OA, diagnosed according to the clinical and radiological criteria of the American College of Rheumatology [<xref ref-type="bibr" rid="CR25">25</xref>], and clinical synovitis, were randomized to explore the effects of chondroitin sulfate (Condrosan&#x000ae;; Bioib&#x000e9;rica S.A.U., Barcelona, Spain) (1200&#x000a0;mg daily; <italic>n</italic>&#x02009;=&#x02009;97) compared to celecoxib (200&#x000a0;mg daily; <italic>n</italic>&#x02009;=&#x02009;97) on cartilage volume loss in knee OA. Celecoxib was chosen as the comparator since, among many other reasons, it was shown to have no&#x000a0;effect on the progression of cartilage volume loss in patients with knee OA [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par30">The original study protocol was approved by a central review board (Institutional Review Board (IRB) Services, Toronto, ON, Canada) and the IRB of the Centre hospitalier de l&#x02019;Universit&#x000e9; de Sherbrooke (CHUS), Sherbrooke, QC, Canada. The original trial [<xref ref-type="bibr" rid="CR6">6</xref>] was conducted in compliance with the ethical principles that have their origin in the Declaration of Helsinki (2000) and are consistent with &#x0201c;Good Clinical Practice&#x0201d; International Conference of Harmonization (ICH) Tripartite Guideline (January 1997) and the applicable laws and regulations of Canada, whichever afforded the greater protection to the individual. Ethical approval for this post hoc study was obtained with the original study, thus further approval was not required. All patients provided informed consent.</p><p id="Par31">The according-to-protocol (ATP) population (chondroitin sulfate <italic>n</italic>&#x02009;=&#x02009;57; celecoxib <italic>n</italic>&#x02009;=&#x02009;62) was chosen as it included patients who fully complied with the study&#x02019;s 2-year protocol and for whom serum and MRI at baseline and at 2&#x000a0;years were available. Of note, compared to the original ATP population [<xref ref-type="bibr" rid="CR6">6</xref>], one serum sample was missing in the celecoxib group. These patients had taken the study medication throughout the entire study period (compliance &#x02265;75%) and had no major protocol violations.</p></sec><sec id="Sec4"><title>Outcome</title><p id="Par32">The primary outcome of the study was the usefulness of some serum biomarkers to indicate patients who are most likely to have reduction in cartilage volume loss in response to chondroitin sulfate. Of note, pain was not considered as an outcome because in the original MOSAIC trial [<xref ref-type="bibr" rid="CR6">6</xref>] both therapeutic groups experienced a comparable reduction in disease-associated pain at 2&#x000a0;years. Moreover, data from the original trial [<xref ref-type="bibr" rid="CR6">6</xref>] showed no difference between the two treatment groups in cartilage volume in the lateral compartment of the knee at baseline or loss of cartilage volume in any comparison; therefore, only the medial compartment of the knee (condyle plus plateau) and its sub-regions (condyle and plateau) were studied.</p></sec><sec id="Sec5"><title>Clinical, structural and biomarker assessments</title><sec id="Sec6"><title>Clinical evaluation at baseline</title><p id="Par33">Clinical evaluation at baseline is shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Chondroitin sulfate (<italic>n</italic>&#x02009;=&#x02009;57)</th><th>Celecoxib (<italic>n</italic>&#x02009;=&#x02009;62)</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td>Male, <italic>n</italic> (%)</td><td>26 (46)</td><td>29 (47)</td><td>0.899*</td></tr><tr><td>Age, years</td><td>61&#x02009;&#x000b1;&#x02009;8</td><td>61&#x02009;&#x000b1;&#x02009;8</td><td>0.909</td></tr><tr><td>Body mass index, kg/m<sup>2</sup>
</td><td>30.3&#x02009;&#x000b1;&#x02009;6.42</td><td>32.5&#x02009;&#x000b1;&#x02009;5.9</td><td>
<italic>0.020</italic>
</td></tr><tr><td>Synovial membrane thickness, mm</td><td>1.04&#x02009;&#x000b1;&#x02009;0.23</td><td>1.01&#x02009;&#x000b1;&#x02009;0.22</td><td>0.528</td></tr><tr><td>Bone marrow lesion, score</td><td>2.49&#x02009;&#x000b1;&#x02009;3.20</td><td>2.63&#x02009;&#x000b1;&#x02009;2.33</td><td>0.291</td></tr><tr><td>Synovial fluid volume, mL</td><td>14.8&#x02009;&#x000b1;&#x02009;15.9</td><td>11.2&#x02009;&#x000b1;&#x02009;12.3</td><td>0.210</td></tr><tr><td>Joint swelling and effusion, <italic>n</italic> (%)</td><td>37 (65)</td><td>32 (52)</td><td>0.142*</td></tr><tr><td>Pain VAS, mm</td><td>60.6&#x02009;&#x000b1;&#x02009;15.9</td><td>57.2&#x02009;&#x000b1;&#x02009;18.6</td><td>0.252</td></tr><tr><td colspan="4">WOMAC</td></tr><tr><td>&#x02003;Total score (0&#x02013;240)</td><td>121&#x02009;&#x000b1;&#x02009;38</td><td>120&#x02009;&#x000b1;&#x02009;46</td><td>0.934</td></tr><tr><td>&#x02003;Pain score (0&#x02013;50)</td><td>24&#x02009;&#x000b1;&#x02009;8</td><td>24&#x02009;&#x000b1;&#x02009;9</td><td>0.909</td></tr><tr><td>&#x02003;Stiffness score (0&#x02013;20)</td><td>11&#x02009;&#x000b1;&#x02009;4</td><td>11&#x02009;&#x000b1;&#x02009;4</td><td>0.694</td></tr><tr><td>Physical function score (0&#x02013;170)</td><td>86&#x02009;&#x000b1;&#x02009;29</td><td>85&#x02009;&#x000b1;&#x02009;34</td><td>0.842</td></tr><tr><td colspan="4">Quality of life (SF-36)</td></tr><tr><td>&#x02003;Physical component summary</td><td>36.31&#x02009;&#x000b1;&#x02009;7.82</td><td>36.33&#x02009;&#x000b1;&#x02009;8.13</td><td>0.610</td></tr><tr><td>Cartilage volume (mm<sup>3</sup>)</td><td/><td/><td/></tr><tr><td colspan="4">Medial</td></tr><tr><td>&#x02003;Compartment</td><td>4586&#x02009;&#x000b1;&#x02009;1517</td><td>4324&#x02009;&#x000b1;&#x02009;1309</td><td>0.445</td></tr><tr><td>&#x02003;Condyle</td><td>2881&#x02009;&#x000b1;&#x02009;1020</td><td>2682&#x02009;&#x000b1;&#x02009;833</td><td>0.448</td></tr><tr><td>&#x02003;Plateau</td><td>1705&#x02009;&#x000b1;&#x02009;545</td><td>1642&#x02009;&#x000b1;&#x02009;532</td><td>0.529</td></tr></tbody></table><table-wrap-foot><p>Data shown are number of patients (%) or mean&#x02009;&#x000b1;&#x02009;SD. Continuous variables were compared using the Student's <italic>t</italic> test/Mann-Whitney test; <italic>p</italic> values in italics are statistically significant. *Proportions were compared using the chi-squared test/Fisher&#x02019;s exact test. <italic>VAS</italic> visual analog scale, <italic>WOMAC</italic> Western Ontario and McMaster Universities Osteoarthritis Index, <italic>SF-36</italic> Short Form 36</p></table-wrap-foot></table-wrap>
</p><p id="Par34">Clinical evaluation at baseline included assessment of knee pain on a visual analog scale (VAS), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores, the quality of life Short Form 36 General Health (SF-36), and clinical examination (swelling, visual examination; effusion, bulge sign).</p></sec><sec id="Sec7"><title>MRI evaluation at baseline</title><p id="Par35">Assessment using MR images included, in addition to cartilage volume [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>] (see subsequent description), the extent of synovitis assessed by measuring synovial thickness (mm) in four regions of interest (ROIs): the medial and lateral articular recess and the medial and lateral outer wall of the suprapatellar bursa [<xref ref-type="bibr" rid="CR29">29</xref>]. The synovial fluid was determined using a fully automated system as previously described [<xref ref-type="bibr" rid="CR30">30</xref>]. Bone marrow lesions were assessed in the same MRI sequences used for the cartilage assessment [<xref ref-type="bibr" rid="CR31">31</xref>], and their extent was evaluated using the following scale: 0, absence; 1, &#x0003c;25%; 2, 25&#x02013;50%; 3, &#x0003e;50% of the surface. The readers were blinded to treatment and to MRI examination time point except for baseline [<xref ref-type="bibr" rid="CR6">6</xref>].</p></sec><sec id="Sec8"><title>Cartilage volume assessment</title><p id="Par36">Cartilage volume was assessed by MRI, which was performed on 1.5&#x000a0;T scanners (Siemens, Erlangen, Germany; General Electric, Milwaukee, WI, USA) using a standard knee coil, and the sequence acquisitions were as previously described [<xref ref-type="bibr" rid="CR32">32</xref>]. The cartilage volume was measured by two experienced readers trained by musculoskeletal radiologists using the computer program Cartiscope&#x02122; (ArthroLab, Montreal, QC, Canada) as previously described [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. The change (percentage) in knee cartilage volume was obtained by subtracting the follow-up volume from the initial (baseline) volume divided by the initial (baseline) volume multiplied by 100. The percent coefficient of variation (CV%) is excellent as described [<xref ref-type="bibr" rid="CR27">27</xref>].</p></sec><sec id="Sec9"><title>Biomarker assessment</title><p id="Par37">Blood samples were obtained after subjects fasted overnight. The samples were first allowed to coagulate and were then centrifuged (2200&#x000a0;rpm/1000&#x000a0;g, 10&#x000a0;minutes). Samples were stored at &#x02013;80&#x000a0;&#x000b0;C until analyzed.</p><p id="Par38">CTX-1 (Neo Scientific, Cambridge, MA, USA), HA (R&#x00026;D Systems, Minneapolis, MN, USA) and PIIANP (EMD Millipore Corporation, Billerica, MA, USA) were assessed using specific ELISAs. Each assay is highly sensitive (sensitivity for CTX-1, 0.1&#x000a0;ng/mL; HA, 0.027&#x000a0;ng/mL; and PIIANP, 30.0&#x000a0;ng/mL) and designed to eliminate interference by other factors present in biological samples. Factors were read with a spectrophotometer (Multiskan Spectrum; Thermo Fisher Scientific, Mississauga, ON, Canada) and analyses performed with SkanIt sofware (Thermo). The CRP data (absolute values) available from the clinical trial report were used. The levels of the adipokines leptin and adipsin, and of MMP-1 and MMP-3 were assessed using the Human Magnetic Luminex Performance Assay kits (R&#x00026;D Systems) in accordance with the manufacturer&#x02019;s instructions with the minimum detectable dose (MDD) of 7.69&#x000a0;ng/mL; 1.8&#x000a0;pg/mL; 0.57&#x000a0;pg/mL and 1.8&#x000a0;pg/mL, respectively. The assessment was performed using a multiplex immunoassay (Luminex Corporation, Austin, TX, USA) on a LiquiChip 200. Analyte-specific antibodies were read using a Luminex analyzer, which discriminates each different analyte, and quantitated using LiquidChip Analyzer (QIAGEN, Toronto, ON, Canada). For each factor, an 8-point standard curve and appropriate controls were included, and samples were done in duplicate.</p></sec></sec><sec id="Sec10"><title>Statistical analyses</title><p id="Par39">Descriptive variables at baseline were presented as number, percentage, or mean&#x02009;&#x000b1;&#x02009;standard deviation (SD) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Differences between the two treatment groups were assessed using Student&#x02019;s <italic>t</italic> test or the Mann-Whitney test for continuous variables with a non-normal distribution, and the chi-squared or Fisher&#x02019;s exact test for categorical variables (Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>). Correlation between all biomarker levels at baseline were carried out using Pearson&#x02019;s correlation analysis in all subjects (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Biomarker levels at baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Chondroitin sulfate (<italic>n</italic>&#x02009;=&#x02009;57)</th><th>Celecoxib (<italic>n</italic>&#x02009;=&#x02009;62)</th><th>
<italic>P</italic> value*</th></tr></thead><tbody><tr><td>CRP, &#x003bc;g/mL<sup>&#x02020;</sup>
</td><td>4.02&#x02009;&#x000b1;&#x02009;5.41 (<italic>n</italic>&#x02009;=&#x02009;48)</td><td>5.56&#x02009;&#x000b1;&#x02009;5.54 (<italic>n</italic>&#x02009;=&#x02009;46)</td><td char="." align="char">
<italic>0.042</italic>
</td></tr><tr><td>HA, ng/mL</td><td>62.46&#x02009;&#x000b1;&#x02009;44.81</td><td>72.46&#x02009;&#x000b1;&#x02009;60.45</td><td char="." align="char">0.267</td></tr><tr><td>Leptin, ng/mL</td><td>37.60&#x02009;&#x000b1;&#x02009;43.78</td><td>44.23&#x02009;&#x000b1;&#x02009;38.53</td><td char="." align="char">0.214</td></tr><tr><td>Adipsin, &#x003bc;g/mL</td><td>4.05&#x02009;&#x000b1;&#x02009;1.07</td><td>4.19&#x02009;&#x000b1;&#x02009;1.07</td><td char="." align="char">0.638</td></tr><tr><td>MMP-1, ng/mL</td><td>5.11&#x02009;&#x000b1;&#x02009;4.13</td><td>4.69&#x02009;&#x000b1;&#x02009;3.15</td><td char="." align="char">0.827</td></tr><tr><td>MMP-3, ng/mL</td><td>13.03&#x02009;&#x000b1;&#x02009;6.31</td><td>13.85&#x02009;&#x000b1;&#x02009;11.04</td><td char="." align="char">0.720</td></tr><tr><td>PIIANP, &#x003bc;g/mL</td><td>4.10&#x02009;&#x000b1;&#x02009;1.92</td><td>4.10&#x02009;&#x000b1;&#x02009;1.61</td><td char="." align="char">0.468</td></tr><tr><td>CTX-1, ng/mL</td><td>0.59&#x02009;&#x000b1;&#x02009;0.18</td><td>0.53&#x02009;&#x000b1;&#x02009;0.12</td><td char="." align="char">
<italic>0.035</italic>
</td></tr></tbody></table><table-wrap-foot><p>Data shown are mean&#x02009;&#x000b1;&#x02009;SD. <italic>CRP</italic> C reactive protein, <italic>HA</italic> hyaluronic acid, <italic>MMP</italic> matrix metalloproteinase, <italic>PIIANP</italic> N-terminal propeptide of collagen II&#x003b1;, <italic>CTX-</italic>1 C-terminal crosslinked telopeptide of type I collagen. *Mann-Whitney test; <italic>p</italic> values in italics are statistically significant. <sup>&#x02020;</sup>Data missing for 25 patients at baseline</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Correlations between the biomarker levels at baseline in all subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th>CRP (<italic>n</italic>&#x02009;=&#x02009;94*)</th><th>HA (<italic>n</italic>&#x02009;=&#x02009;119)</th><th>Leptin (<italic>n</italic>&#x02009;=&#x02009;119)</th><th>Adipsin (<italic>n</italic>&#x02009;=&#x02009;119)</th><th>MMP-1 (<italic>n</italic>&#x02009;=&#x02009;119)</th><th>MMP-3 (<italic>n</italic>&#x02009;=&#x02009;119)</th><th>PIIANP (<italic>n</italic>&#x02009;=&#x02009;119)</th><th>CTX-1 (<italic>n</italic>&#x02009;=&#x02009;117**)</th></tr></thead><tbody><tr><td>CRP</td><td>
<italic>r</italic>
</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td/><td>
<italic>p</italic> value<sup>&#x02020;</sup>
</td><td>-</td><td>-</td><td>-</td><td>-</td><td>
<bold>-</bold>
</td><td>-</td><td>-</td><td>-</td></tr><tr><td>HA</td><td>
<italic>r</italic>
</td><td>&#x0003c;0.0001</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td/><td>
<italic>p</italic> value</td><td>&#x0003e;0.999</td><td>-</td><td>-</td><td>-</td><td>-</td><td>
<bold>-</bold>
</td><td>-</td><td>
<bold>-</bold>
</td></tr><tr><td>Leptin</td><td>
<italic>r</italic>
</td><td>0.344</td><td>-0.006</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td/><td>
<italic>p</italic> value</td><td>
<italic>0.001</italic>
</td><td>0.947</td><td>-</td><td>-</td><td>-</td><td>-</td><td>
<bold>-</bold>
</td><td>-</td></tr><tr><td>Adipsin</td><td>
<italic>r</italic>
</td><td>-0.016</td><td>0.188</td><td>0.343</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td/><td>
<italic>p</italic> value</td><td>0.881</td><td>
<italic>0.040</italic>
</td><td>
<italic>0.001</italic>
</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>MMP-1</td><td>
<italic>r</italic>
</td><td>0.045</td><td>-0.009</td><td>0.036</td><td>0.234</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td/><td>
<italic>p</italic> value</td><td>0.664</td><td>0.922</td><td>0.702</td><td>
<italic>0.010</italic>
</td><td>-</td><td>
<bold>-</bold>
</td><td>-</td><td>
<bold>-</bold>
</td></tr><tr><td>MMP-3</td><td>
<italic>r</italic>
</td><td>0.051</td><td>0.195</td><td>-0.245</td><td>0.049</td><td>-0.064</td><td>-</td><td>-</td><td>-</td></tr><tr><td/><td>
<italic>p</italic> value</td><td>0.627</td><td>
<italic>0.033</italic>
</td><td>
<italic>0.007</italic>
</td><td>0.594</td><td>0.489</td><td>-</td><td>
<bold>-</bold>
</td><td>-</td></tr><tr><td>PIIANP</td><td>
<italic>r</italic>
</td><td>0.025</td><td>-0.042</td><td>0.015</td><td>-0.059</td><td>-0.277</td><td>-0.070</td><td>-</td><td>-</td></tr><tr><td/><td>
<italic>p</italic> value</td><td>0.813</td><td>0.650</td><td>0.875</td><td>0.524</td><td>
<italic>0.002</italic>
</td><td>0.451</td><td>-</td><td>-</td></tr><tr><td>CTX-1</td><td>
<italic>r</italic>
</td><td>-0.093</td><td>0.063</td><td>0.016</td><td>-0.105</td><td>-0.049</td><td>-0.099</td><td>0.075</td><td>-</td></tr><tr><td/><td>
<italic>p</italic> value</td><td>0.380</td><td>0.497</td><td>0.862</td><td>0.262</td><td>0.601</td><td>0.287</td><td>0.422</td><td>-</td></tr></tbody></table><table-wrap-foot><p>
<italic>CRP</italic> C reactive protein, <italic>HA</italic> hyaluronic acid, <italic>MMP</italic> matrix metalloproteinase, <italic>PIIANP</italic> N-terminal propeptide of collagen II&#x003b1;, <italic>CTX-</italic>1 C-terminal crosslinked telopeptide of type I collagen. *Data missing for 25 patients at baseline; **data missing for 2 patients at baseline</p><p>
<sup>&#x02020;</sup>Pearson&#x02019;s correlation; <italic>p </italic> values in italics are statistically significant</p></table-wrap-foot></table-wrap>
</p><p id="Par40">Linear regressions adjusting for age, gender and body mass index (BMI) were also carried out to assess associations between baseline serum levels of the biomarkers and cartilage volume at baseline, and volume loss over 2&#x000a0;years within the medial compartment, medial condyle and medial plateau in all subjects (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Associations between cartilage volume and its loss and biomarker levels at baseline for all subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th>CRP (<italic>n</italic>&#x02009;=&#x02009;94*)</th><th>HA (<italic>n</italic>&#x02009;=&#x02009;119)</th><th>Leptin (<italic>n</italic>&#x02009;=&#x02009;119)</th><th>Adipsin (<italic>n</italic>&#x02009;=&#x02009;119)</th><th>MMP-1 (<italic>n</italic>&#x02009;=&#x02009;119)</th><th>MMP-3 (<italic>n</italic>&#x02009;=&#x02009;119)</th><th>PIIANP (<italic>n</italic>&#x02009;=&#x02009;119)</th><th>CTX-1 (<italic>n</italic>&#x02009;=&#x02009;117**)</th></tr></thead><tbody><tr><td colspan="10">Cartilage volume at baseline</td></tr><tr><td>Medial compartment</td><td>&#x003b2;</td><td char="." align="char">-49.24</td><td char="." align="char">-1.66</td><td char="." align="char">-4.26</td><td>101.26</td><td char="." align="char">-2.49</td><td char="." align="char">9.35</td><td char="." align="char">-40.65</td><td>-773.37</td></tr><tr><td/><td>
<italic>p</italic> value<sup>&#x02020;</sup>
</td><td char="." align="char">
<italic>0.045</italic>
</td><td char="." align="char">0.409</td><td char="." align="char">0.385</td><td>0.315</td><td char="." align="char">0.931</td><td char="." align="char">0.454</td><td char="." align="char">0.489</td><td>0.256</td></tr><tr><td>Medial condyle</td><td>&#x003b2;</td><td char="." align="char">-37.09</td><td char="." align="char">-0.75</td><td char="." align="char">-2.62</td><td>74.50</td><td char="." align="char">-1.99</td><td char="." align="char">7.41</td><td char="." align="char">-38.66</td><td>-407.44</td></tr><tr><td/><td>
<italic>p</italic> value</td><td char="." align="char">
<italic>0.030</italic>
</td><td char="." align="char">0.591</td><td char="." align="char">0.441</td><td>0.287</td><td char="." align="char">0.920</td><td char="." align="char">0.392</td><td char="." align="char">0.342</td><td>0.389</td></tr><tr><td>Medial plateau</td><td>&#x003b2;</td><td char="." align="char">-12.15</td><td char="." align="char">-0.91</td><td char="." align="char">-1.63</td><td>26.77</td><td char="." align="char">-0.50</td><td char="." align="char">1.94</td><td char="." align="char">-1.99</td><td>-365.94</td></tr><tr><td/><td>
<italic>p</italic> value</td><td char="." align="char">0.170</td><td char="." align="char">0.215</td><td char="." align="char">0.361</td><td>0.468</td><td char="." align="char">0.962</td><td char="." align="char">0.671</td><td char="." align="char">0.926</td><td>0.141</td></tr><tr><td colspan="10">Cartilage volume loss at 2&#x000a0;years</td></tr><tr><td>Medial compartment</td><td>&#x003b2;</td><td char="." align="char">-0.179</td><td char="." align="char">0.001</td><td char="." align="char">0.009</td><td>0.334</td><td char="." align="char">0.049</td><td char="." align="char">-0.022</td><td char="." align="char">-0.546</td><td>3.418</td></tr><tr><td/><td>
<italic>p</italic> value</td><td char="." align="char">
<italic>0.029</italic>
</td><td char="." align="char">0.905</td><td char="." align="char">0.590</td><td>0.342</td><td char="." align="char">0.622</td><td char="." align="char">0.615</td><td char="." align="char">
<italic>0.007</italic>
</td><td>0.150</td></tr><tr><td>Medial condyle</td><td>&#x003b2;</td><td char="." align="char">-0.184</td><td char="." align="char">0.004</td><td char="." align="char">-0.012</td><td>0.275</td><td char="." align="char">0.137</td><td char="." align="char">-0.038</td><td char="." align="char">-0.606</td><td>2.792</td></tr><tr><td/><td>
<italic>p</italic> value</td><td char="." align="char">
<italic>0.050</italic>
</td><td char="." align="char">0.643</td><td char="." align="char">0.560</td><td>0.501</td><td char="." align="char">0.235</td><td char="." align="char">0.455</td><td char="." align="char">
<italic>0.010</italic>
</td><td>0.313</td></tr><tr><td>Medial plateau</td><td>&#x003b2;</td><td char="." align="char">-0.164</td><td char="." align="char">-0.005</td><td char="." align="char">0.049</td><td>0.415</td><td char="." align="char">-0.100</td><td char="." align="char">-0.001</td><td char="." align="char">-0.420</td><td>4.532</td></tr><tr><td/><td>
<italic>p</italic> value</td><td char="." align="char">0.102</td><td char="." align="char">0.512</td><td char="." align="char">
<italic>0.016</italic>
</td><td>0.321</td><td char="." align="char">0.402</td><td char="." align="char">0.989</td><td char="." align="char">0.083</td><td>0.106</td></tr></tbody></table><table-wrap-foot><p>
<italic>CRP</italic> C reactive protein, <italic>HA</italic> hyaluronic acid, <italic>MMP</italic> matrix metalloproteinase, <italic>PIIANP</italic> N-terminal propeptide of collagen II&#x003b1;, <italic>CTX-</italic>1 C-terminal crosslinked telopeptide of type I collagen, <italic>&#x003b2;</italic> regression parameter estimate of the biomarker. *Data missing for 25 patients at baseline; **data missing for 2 patients at baseline. <sup>&#x02020;</sup>Linear regression adjusted for age, gender and body mass index; <italic>p </italic> values in italics are statistically significant</p></table-wrap-foot></table-wrap>
</p><p id="Par41">Since serum biomarkers are relatively new to the OA field in the context of a clinical trial, the median baseline biomarker levels were used to discriminate for the overall cohort (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1) and within the treatment groups (chondroitin sulfate vs. celecoxib) (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>, Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2) to assess associations with baseline cartilage volume (medial compartment, medial condyle and medial plateau) and the predictive power of change in cartilage volume in the same regions at 2&#x000a0;years. The difference between mean cartilage volume within the three knee areas for lower vs. higher median biomarker levels was assessed by univariate analysis using Student&#x02019;s <italic>t</italic> test or the Mann-Whitney test if the distribution was non-normal distribution (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2).<table-wrap id="Tab5"><label>Table 5</label><caption><p>Two-year medial region cartilage volume loss (%) according to median value of baseline biomarker levels per treatment group</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="3">Lower than median</th><th colspan="3">Higher than median</th></tr><tr><th>Chondroitin Sulfate</th><th>Celecoxib</th><th>
<italic>P</italic> value<sup>&#x02020;</sup>
</th><th>Chondroitin Sulfate</th><th>Celecoxib</th><th>
<italic>P</italic> value<sup>&#x02020;</sup>
</th></tr></thead><tbody><tr><td>CRP<sup>a</sup> (<italic>n</italic>&#x02009;=&#x02009;94)* Median 3.2&#x000a0;&#x003bc;g/mL</td><td/><td/><td/><td/><td/><td/></tr><tr><td>
<italic>n</italic>
</td><td>28</td><td>19</td><td/><td>20</td><td>27</td><td/></tr><tr><td>Medial compartment</td><td>-6.00&#x02009;&#x000b1;&#x02009;3.31</td><td>-7.40&#x02009;&#x000b1;&#x02009;3.81</td><td>0.237</td><td>-7.21&#x02009;&#x000b1;&#x02009;3.49</td><td>-8.63&#x02009;&#x000b1;&#x02009;4.65</td><td>0.510</td></tr><tr><td>Medial condyle</td><td>-5.13&#x02009;&#x000b1;&#x02009;4.05</td><td>-6.99&#x02009;&#x000b1;&#x02009;4.46</td><td>0.188</td><td>-6.05&#x02009;&#x000b1;&#x02009;4.22</td><td>-8.28&#x02009;&#x000b1;&#x02009;4.90</td><td>0.211</td></tr><tr><td>Medial plateau</td><td>-7.40&#x02009;&#x000b1;&#x02009;3.90</td><td>-7.91&#x02009;&#x000b1;&#x02009;4.49</td><td>0.745</td><td>-9.10&#x02009;&#x000b1;&#x02009;5.12</td><td>-9.14&#x02009;&#x000b1;&#x02009;5.56</td><td>0.642</td></tr><tr><td>HA<sup>a</sup> (<italic>n</italic>&#x02009;=&#x02009;119) Median 50.2&#x000a0;ng/mL</td><td/><td/><td/><td/><td/><td/></tr><tr><td>
<italic>n</italic>
</td><td>31</td><td>28</td><td/><td>34</td><td>26</td><td/></tr><tr><td>Medial compartment</td><td>-5.85&#x02009;&#x000b1;&#x02009;3.24</td><td>-8.90&#x02009;&#x000b1;&#x02009;3.95</td><td>0.083</td><td>-7.45&#x02009;&#x000b1;&#x02009;3.11</td><td>-8.10&#x02009;&#x000b1;&#x02009;4.46</td><td>0.629</td></tr><tr><td>Medial condyle</td><td>-4.99&#x02009;&#x000b1;&#x02009;4.03</td><td>-8.57&#x02009;&#x000b1;&#x02009;4.79</td><td>
<italic>0.047</italic>
</td><td>-6.61&#x02009;&#x000b1;&#x02009;3.89</td><td>-7.73&#x02009;&#x000b1;&#x02009;4.74</td><td>0.334</td></tr><tr><td>Medial clateau</td><td>-7.12&#x02009;&#x000b1;&#x02009;3.74</td><td>-9.32&#x02009;&#x000b1;&#x02009;4.32</td><td>0.275</td><td>-8.98&#x02009;&#x000b1;&#x02009;4.50</td><td>-8.71&#x02009;&#x000b1;&#x02009;5.33</td><td>0.671</td></tr><tr><td>LEPTIN<sup>b</sup> (<italic>n</italic>&#x02009;=&#x02009;119) Median 24.9&#x000a0;ng/ml</td><td/><td/><td/><td/><td/><td/></tr><tr><td>
<italic>n</italic>
</td><td>30</td><td>30</td><td/><td>27</td><td>32</td><td/></tr><tr><td>Medial compartment</td><td>-6.58&#x02009;&#x000b1;&#x02009;3.12</td><td>-9.42&#x02009;&#x000b1;&#x02009;4.50</td><td>
<italic>0.011</italic>
</td><td>-6.58&#x02009;&#x000b1;&#x02009;3.45</td><td>-7.61&#x02009;&#x000b1;&#x02009;3.89</td><td>0.445</td></tr><tr><td>Medial condyle</td><td>-5.90&#x02009;&#x000b1;&#x02009;3.93</td><td>-9.16&#x02009;&#x000b1;&#x02009;5.40</td><td>
<italic>0.014</italic>
</td><td>-5.54&#x02009;&#x000b1;&#x02009;4.17</td><td>-7.16&#x02009;&#x000b1;&#x02009;3.99</td><td>0.227</td></tr><tr><td>Medial plateau</td><td>-7.64&#x02009;&#x000b1;&#x02009;3.08</td><td>-9.90&#x02009;&#x000b1;&#x02009;4.90</td><td>
<italic>0.037</italic>
</td><td>-8.34&#x02009;&#x000b1;&#x02009;5.17</td><td>-8.20&#x02009;&#x000b1;&#x02009;4.85</td><td>0.846</td></tr><tr><td>ADIPSIN<sup>b</sup> (n&#x02009;=&#x02009;119) Median 4.1&#x000a0;&#x003bc;g/mL</td><td/><td/><td/><td/><td/><td/></tr><tr><td>
<italic>n</italic>
</td><td>31</td><td>29</td><td/><td>26</td><td>33</td><td/></tr><tr><td>Medial compartment</td><td>-6.48&#x02009;&#x000b1;&#x02009;3.06</td><td>-8.76&#x02009;&#x000b1;&#x02009;4.40</td><td>
<italic>0.040</italic>
</td><td>-6.70&#x02009;&#x000b1;&#x02009;3.53</td><td>-8.20&#x02009;&#x000b1;&#x02009;4.11</td><td>0.161</td></tr><tr><td>Medial condyle</td><td>-5.16&#x02009;&#x000b1;&#x02009;3.83</td><td>-8.38&#x02009;&#x000b1;&#x02009;4.97</td><td>
<italic>0.007</italic>
</td><td>-6.42&#x02009;&#x000b1;&#x02009;4.19</td><td>-7.88&#x02009;&#x000b1;&#x02009;4.60</td><td>0.249</td></tr><tr><td>Medial plateau</td><td>-8.64&#x02009;&#x000b1;&#x02009;4.14</td><td>-9.35&#x02009;&#x000b1;&#x02009;5.21</td><td>0.701</td><td>-7.16&#x02009;&#x000b1;&#x02009;4.15</td><td>-8.67&#x02009;&#x000b1;&#x02009;4.61</td><td>0.190</td></tr><tr><td>MMP-1<sup>c</sup> (<italic>n</italic>&#x02009;=&#x02009;119) Median 3.6&#x000a0;ng/mL</td><td/><td/><td/><td/><td/><td/></tr><tr><td>
<italic>n</italic>
</td><td>25</td><td>34</td><td/><td>32</td><td>28</td><td/></tr><tr><td>Medial compartment</td><td>-7.12&#x02009;&#x000b1;&#x02009;3.38</td><td>-8.44&#x02009;&#x000b1;&#x02009;3.68</td><td>0.239</td><td>-6.16&#x02009;&#x000b1;&#x02009;3.14</td><td>-8.49&#x02009;&#x000b1;&#x02009;4.86</td><td>
<italic>0.050</italic>
</td></tr><tr><td>Medial condyle</td><td>-6.29&#x02009;&#x000b1;&#x02009;4.47</td><td>-8.20&#x02009;&#x000b1;&#x02009;4.41</td><td>0.165</td><td>-5.30&#x02009;&#x000b1;&#x02009;3.63</td><td>-8.01&#x02009;&#x000b1;&#x02009;5.20</td><td>
<italic>0.028</italic>
</td></tr><tr><td>Medial plateau</td><td>-8.53&#x02009;&#x000b1;&#x02009;3.48</td><td>-8.77&#x02009;&#x000b1;&#x02009;4.46</td><td>0.908</td><td>-7.53&#x02009;&#x000b1;&#x02009;4.65</td><td>-9.26&#x02009;&#x000b1;&#x02009;5.40</td><td>0.269</td></tr><tr><td>MMP-3<sup>c</sup> (<italic>n</italic>&#x02009;=&#x02009;119) Median 11.2&#x000a0;ng/mL</td><td/><td/><td/><td/><td/><td/></tr><tr><td>
<italic>n</italic>
</td><td>27</td><td>32</td><td/><td>30</td><td>30</td><td/></tr><tr><td>Medial compartment</td><td>-7.10&#x02009;&#x000b1;&#x02009;3.26</td><td>-7.29&#x02009;&#x000b1;&#x02009;4.26</td><td>0.945</td><td>-6.12&#x02009;&#x000b1;&#x02009;3.23</td><td>-9.72&#x02009;&#x000b1;&#x02009;3.86</td><td>
<italic>0.001</italic>
</td></tr><tr><td>Medial condyle</td><td>-6.39&#x02009;&#x000b1;&#x02009;3.81</td><td>-6.94&#x02009;&#x000b1;&#x02009;4.45</td><td>0.765</td><td>-5.15&#x02009;&#x000b1;&#x02009;4.16</td><td>-9.37&#x02009;&#x000b1;&#x02009;4.79</td><td>
<italic>0.001</italic>
</td></tr><tr><td>Medial plateau</td><td>-8.21&#x02009;&#x000b1;&#x02009;4.53</td><td>-7.67&#x02009;&#x000b1;&#x02009;5.04</td><td>0.736</td><td>-7.75&#x02009;&#x000b1;&#x02009;3.89</td><td>-10.40&#x02009;&#x000b1;&#x02009;4.34</td><td>
<italic>0.048</italic>
</td></tr><tr><td>PIIANP<sup>d</sup> (<italic>n</italic>&#x02009;=&#x02009;119) Median 3.9&#x000a0;&#x003bc;g/mL</td><td/><td/><td/><td/><td/><td/></tr><tr><td>
<italic>n</italic>
</td><td>28</td><td>31</td><td/><td>29</td><td>31</td><td/></tr><tr><td>Medial compartment</td><td>-5.59&#x02009;&#x000b1;&#x02009;2.96</td><td>-7.45&#x02009;&#x000b1;&#x02009;4.02</td><td>0.115</td><td>-7.54&#x02009;&#x000b1;&#x02009;3.28</td><td>-9.48&#x02009;&#x000b1;&#x02009;4.23</td><td>0.070</td></tr><tr><td>Medial condyle</td><td>-4.91&#x02009;&#x000b1;&#x02009;4.00</td><td>-6.97&#x02009;&#x000b1;&#x02009;4.43</td><td>0.164</td><td>-6.52&#x02009;&#x000b1;&#x02009;3.93</td><td>-9.25&#x02009;&#x000b1;&#x02009;4.84</td><td>
<italic>0.026</italic>
</td></tr><tr><td>Medial plateau</td><td>-6.52&#x02009;&#x000b1;&#x02009;3.23</td><td>-8.27&#x02009;&#x000b1;&#x02009;5.04</td><td>0.129</td><td>-9.37&#x02009;&#x000b1;&#x02009;4.54</td><td>-9.71&#x02009;&#x000b1;&#x02009;4.67</td><td>0.829</td></tr><tr><td>CTX-1<sup>d</sup> (<italic>n</italic>&#x02009;=&#x02009;117)** Median 0.53&#x000a0;ng/mL</td><td/><td/><td/><td/><td/><td/></tr><tr><td>
<italic>n</italic>
</td><td>23</td><td>35</td><td/><td>33</td><td>26</td><td/></tr><tr><td>Medial compartment</td><td>-7.11&#x02009;&#x000b1;&#x02009;3.46</td><td>-8.83&#x02009;&#x000b1;&#x02009;4.14</td><td>0.170</td><td>-6.15&#x02009;&#x000b1;&#x02009;3.13</td><td>-7.83&#x02009;&#x000b1;&#x02009;4.37</td><td>0.085</td></tr><tr><td>Medial condyle</td><td>-6.43&#x02009;&#x000b1;&#x02009;4.08</td><td>-8.38&#x02009;&#x000b1;&#x02009;4.65</td><td>0.186</td><td>-5.20&#x02009;&#x000b1;&#x02009;4.01</td><td>-7.67&#x02009;&#x000b1;&#x02009;5.00</td><td>
<italic>0.025</italic>
</td></tr><tr><td>Medial plateau</td><td>-8.03&#x02009;&#x000b1;&#x02009;4.14</td><td>-9.56&#x02009;&#x000b1;&#x02009;4.78</td><td>0.237</td><td>-7.87&#x02009;&#x000b1;&#x02009;4.29</td><td>-7.99&#x02009;&#x000b1;&#x02009;4.89</td><td>0.931</td></tr></tbody></table><table-wrap-foot><p>Data are cartilage volume loss (%) expressed as mean&#x02009;&#x000b1;&#x02009;SD. <italic>CRP</italic> C reactive protein, <italic>HA</italic> hyaluronic acid, <italic>MMP</italic> matrix metalloproteinase, <italic>PIIANP</italic> N-terminal propeptide of collagen II&#x003b1;, <italic>CTX-</italic>1 C-terminal crosslinked telopeptide of type I collagen. Biomarkers related to <sup>a</sup>inflammation; <sup>b</sup>adipokines; <sup>c</sup>matrix metalloproteinases; <sup>d</sup>collagen metabolism. <sup>&#x02020;</sup>Analysis of covariance adjusted for age, gender, body mass index and, for HA only, cartilage volume at baseline; <italic>p</italic> values in italics are statistically significant. *Data missing for 25 patients at baseline; **data missing for 2 patients at baseline</p></table-wrap-foot></table-wrap>
</p><p id="Par42">Multivariate analyses (ANCOVA) were performed adjusting for the potential confounding factors at the onset of the study, including age, gender, BMI, and baseline cartilage volume for HA only (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>), as it is the only biomarker that showed, in patients with levels lower than the median, a statistically significant difference in the medial condyle between treatment groups (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2).</p><p id="Par43">All tests were two-sided and a <italic>p</italic> value &#x0003c;0.05 was considered statistically significant. Since this was an exploratory study, no statistical corrections were made for multiple comparisons. All statistical analyses were performed using SAS software, version 9.3 (SAS Institute, Cary, NC, USA).</p></sec></sec><sec id="Sec11" sec-type="results"><title>Results</title><sec id="Sec12"><title>Baseline demographic, clinical, and imaging data</title><p id="Par44">The two therapeutic groups were balanced with the exception of BMI, which was slightly higher in the celecoxib group than in the chondroitin sulfate group (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p></sec><sec id="Sec13"><title>Biomarkers</title><sec id="Sec14"><title>Baseline levels</title><p id="Par45">In the study population, with the exception of lower values of CRP and higher values of CTX-1 in the chondroitin sulfate group, there was no significant difference between the two groups (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The differences in the levels of CTX-1, although statistically significant, were very small and unlikely to be clinically relevant. Moreover, those differences found for CRP and CTX-1 no longer existed when the data were stratified by the median value (data not shown).</p></sec><sec id="Sec15"><title>Correlations between biomarker levels</title><p id="Par46">There was positive correlation between levels (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>) of CRP and leptin, HA and adipsin, HA and MMP-3, leptin and adipsin, and adipsin and MMP-1. There was negative correlation between MMP-1 and PIIANP, and between leptin and MMP-3.</p></sec><sec id="Sec16"><title>Associations between biomarkers and cartilage volume</title><p id="Par47">A statistically significant negative adjusted (age, gender, BMI) linear association was found between the level of CRP and cartilage volume in the medial compartment and condyle at baseline (<italic>p</italic>&#x02009;=&#x02009;0.045 and <italic>p</italic>&#x02009;=&#x02009;0.030, respectively) (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). A statistically significant negative adjusted association was also found between the levels of CRP and PIIANP and cartilage volume loss: medial compartment (<italic>p</italic>&#x02009;=&#x02009;0.029 and <italic>p</italic>&#x02009;=&#x02009;0.007, respectively) and condyle (<italic>p</italic>&#x02009;=&#x02009;0.050 and <italic>p</italic>&#x02009;=&#x02009;0.010, respectively). A statistically significant positive adjusted association was found between the level of leptin and cartilage volume loss in the plateau (<italic>p</italic>&#x02009;=&#x02009;0.016).</p></sec><sec id="Sec17"><title>Biomarker and cartilage volume levels at baseline and treatment effects</title><p id="Par48">Since this work is among the first attempts to assess the impact of the studied biomarkers on knee OA structure as assessed by qMRI in relation to OA treatment, and no a priori cutoff values were available, we elected, as mentioned in &#x0201c;Statistical analysis&#x0201d;, to stratify the biomarkers at baseline according to their median levels. First, there were no differences in the cartilage volume between the two stratifications for any of the biomarkers (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). There were also no significant differences between the two treatment groups for each biomarker with the exception of HA, which, at baseline levels lower than the median, showed a statistically significant increase (<italic>p</italic>&#x02009;=&#x02009;0.030) in volume for chondroitin sulfate vs. celecoxib (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2).</p><p id="Par49">Of all of the biomarkers studied (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>), only CRP did not show any difference in the extent of cartilage volume loss between the treatment groups, in either the lower or higher median group. The levels of all the other biomarkers were able to discriminate the extent of cartilage degradation between the treatment groups.</p><p id="Par50">With regard to the biomarkers of inflammation (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>), compared to celecoxib, patients with levels of HA lower than the median treated with chondroitin sulfate demonstrated less cartilage volume loss in the medial condyle (<italic>p</italic>&#x02009;=&#x02009;0.047), with a numerical trend toward significance in the compartment (<italic>p</italic>&#x02009;=&#x02009;0.083).</p><p id="Par51">Similarly, the lower levels of the two studied adipokines (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>), factors involved in inflammation and in cartilage catabolism, showed differentiation between the two treatment groups, with patients treated with chondroitin sulfate having less cartilage volume loss than with celecoxib. This was found in all medial sub-regions for leptin (<italic>p</italic>&#x02009;&#x02264;&#x02009;0.037), and in the compartment (<italic>p</italic>&#x02009;=&#x02009;0.040) and condyle (<italic>p</italic>&#x02009;=&#x02009;0.007) for adipsin.</p><p id="Par52">In contrast, for MMP-1 and MMP-3 (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>), it was in patients with the higher levels that differences between the two treatment groups were found: for MMP-1, patients treated with chondroitin sulfate had less cartilage volume loss than with celecoxib in the medial compartment (<italic>p</italic>&#x02009;=&#x02009;0.050) and condyle (<italic>p</italic>&#x02009;=&#x02009;0.028), and for MMP-3 in the medial compartment (<italic>p</italic>&#x02009;=&#x02009;0.001) and both the condyle (<italic>p</italic>&#x02009;=&#x02009;0.001) and plateau (<italic>p</italic>&#x02009;=&#x02009;0.048).</p><p id="Par53">For PIIANP and CTX-1 (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>), which are biomarkers related to collagen anabolism and catabolism, respectively, patients with higher baseline levels that were treated with chondroitin sulfate had less cartilage volume loss in the medial condyle compared to the celecoxib group (<italic>p</italic>&#x02009;&#x02264;&#x02009;0.026).</p></sec></sec></sec><sec id="Sec18" sec-type="discussion"><title>Discussion</title><p id="Par54">Disease-modifying OA drug trials would benefit from the availability of biomarkers that could predict patients who are most likely to be responsive to a given treatment. The present study, although exploratory, provides important and novel information about the association of some serum biomarker levels with cartilage degradation, which could help to identify such patients. The original trial [<xref ref-type="bibr" rid="CR6">6</xref>] demonstrated that chondroitin sulfate treatment in patients with knee OA had a significant beneficial effect on cartilage volume loss in the medial compartment (condyle). Here, we further showed that higher baseline values of the biomarkers PIIANP, CTX-1, MMP-1, and MMP-3, and lower baseline values of HA, leptin and adipsin seem to be associated with response to chondroitin sulfate treatment in reducing cartilage loss in patients with knee OA.</p><p id="Par55">Data first showed that the extent of systemic inflammation at baseline, assessed by the levels of CRP and HA, positively correlated with the levels of cartilage catabolic factors such as leptin, adipsin, and MMP-3. Moreover, the level of leptin, an adipokine associated with inflammation, was found to positively correlate with the level of another adipokine, adipsin, which was also shown to be associated with cartilage degradation [<xref ref-type="bibr" rid="CR24">24</xref>]. Interestingly, the inverse correlation between the levels of PIIANP and MMP-1 could likely reflect increased turnover and loss of type II collagen in cartilage, as PIIANP is associated with collagen formation/repair and MMP-1 with this macromolecule&#x02019;s degradation. From these data, it can be hypothesized that joint inflammation often seen in knee OA and reflected by an increased level of CRP or HA, may induce an increase in the level of leptin and, secondarily, catabolic factors such as adipsin and MMPs [<xref ref-type="bibr" rid="CR33">33</xref>], leading to cartilage degradation and loss, the latter reflected by negative correlation with PIIANP levels. Such a hypothesis is supported by the findings of this study, which show a negative association between the level of CRP at baseline and the cartilage volume at baseline, and cartilage loss at 2&#x000a0;years. This is well in line with a recent review on several related studies [<xref ref-type="bibr" rid="CR34">34</xref>]. Our findings also concur with previous reports in which the level of CRP is correlated with disease progression in patients with knee OA assessed by X-rays and MRI, and an elevated level is associated with poorer disease outcome [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref>]. However, these findings have not yet attained unanimity [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par56">This study also showed that lower baseline values of leptin, adipsin and HA, and higher values of MMP-3 and MMP-1, were associated with greater reduction in cartilage volume loss with chondroitin sulfate than celecoxib. This suggests that patients with a milder level of inflammation, yet sufficient to induce the synthesis of cartilage catabolic factors (MMPs), and greater cartilage catabolism and disease progression [<xref ref-type="bibr" rid="CR23">23</xref>], are more likely to be responsive to treatment with chondroitin sulfate. These findings are in line with those of previous studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR40">40</xref>] that reported that OA patients who had a better response to glucosamine plus chondroitin sulfate treatment were those with less severe disease but greater cartilage degradation.</p><p id="Par57">HA was found to be more strongly associated with the response to treatment with chondroitin sulfate than CRP. It could be speculated that HA may be more specific than CRP at assessing synovial inflammation. One might argue that the celecoxib treated patients had significantly higher CRP values at baseline and therefore a more severe degree of inflammation, which could have precluded a response to treatment. However, the stratification of patients based on the median value of CRP, which did not differ between treatment subgroups, does not provide support for such a hypothesis. HA has been found to be correlated with symptoms (WOMAC score) and with the degree of radiographic evidence of the disease (Kellgren-Lawrence (KL) grade) [<xref ref-type="bibr" rid="CR41">41</xref>]. In the present study, patients with lower HA were more responsive to treatment with chondroitin sulfate, which, from the aforementioned findings and those in the review by Singh et al. [<xref ref-type="bibr" rid="CR41">41</xref>], could mean that patients with less cartilage damage had a better response to this treatment.</p><p id="Par58">The aforementioned data also agree with those from the adipokines, in that patients treated with chondroitin sulfate who had lower baseline levels of adipokines had less pronounced cartilage loss and likely less synovial inflammation [<xref ref-type="bibr" rid="CR42">42</xref>], a finding that is in line with those related to HA. This has potential clinical relevance because leptin and adipsin have been associated not only with synovial inflammation but also with OA progression and cartilage degradation in both knee and hip OA as assessed by qMRI [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>] and with the incidence of total knee replacement [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par59">There was also evidence that the level of type II collagen synthesis in OA cartilage, assessed by measuring PIIANP, was clearly associated with response to treatment. The beneficial effect of chondroitin sulfate observed in patients with higher PIIANP values, which is usually indicative of less advanced disease [<xref ref-type="bibr" rid="CR45">45</xref>], also supports the aforementioned assumption that the response to such treatment may be more pronounced in these patients.</p><p id="Par60">The protective effect of chondroitin sulfate in patients with higher levels of CTX-I, reflecting an increase in the turnover of type I collagen in bone, is interesting and may possibly be related to the positive effect of chondroitin sulfate on bone marrow lesions [<xref ref-type="bibr" rid="CR8">8</xref>] and on mechanisms related to the remodeling of bone in OA patients [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR46">46</xref>].</p><p id="Par61">This study has limitations, the main one being related to the fact that the original study [<xref ref-type="bibr" rid="CR6">6</xref>] was exploratory and therefore the analysis was performed on the available samples, which were from a limited number of patients. The absence of correction for multiple comparisons is also a study limitation, but should be taken in the context of an exploratory trial. Nevertheless, findings from this study agree with some [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR54">54</xref>], but not all [<xref ref-type="bibr" rid="CR55">55</xref>&#x02013;<xref ref-type="bibr" rid="CR58">58</xref>], previous trials/studies and meta-analyses. Pain could not be considered as a variable, as in the original MOSAIC trial [<xref ref-type="bibr" rid="CR6">6</xref>] chondroitin sulfate showed a beneficial effect comparable to that of celecoxib. The data on CTX-1 were obtained from serum samples as, unfortunately, urine samples were not available. This could have had an impact on the correlation with other biomarkers. The absence of correlation between CRP and HA was somewhat surprising; the smaller number of samples for CRP could potentially have impacted the results of the analysis. Finally, the use of qMRI to assess the overall cartilage loss over time in knee OA provides a global appreciation of the change in knee cartilage volume in specific anatomical areas and represents a summation of cartilage loss (negative value) and areas of cartilage swelling (positive value), both of which are part of the OA cartilage changes observed during the evolution of knee OA.</p></sec><sec id="Sec19" sec-type="conclusion"><title>Conclusion</title><p id="Par62">Although this study is exploratory and should be replicated with a larger number of patients to fully confirm the findings, data indicate that higher baseline values of the biomarkers related to collagen metabolism, PIIANP and CTX-1, and those related to cartilage degradation, MMP-1 and MMP-3, and lower baseline values of biomarkers related to inflammation, HA, leptin and adipsin, seem to be related to better response to chondroitin sulfate treatment in patients with knee OA. This is supportive of a potentially better response to treatment with chondroitin sulfate on cartilage volume loss in patients with knee OA with greater levels of cartilage catabolism and/or lower levels of inflammation.</p></sec></body><back><app-group><app id="App1"><sec id="Sec20"><title>Additional file</title><p id="Par68">
<media position="anchor" xlink:href="13075_2017_1377_MOESM1_ESM.pdf" id="MOESM1"><label>Additional file 1: Table S1.</label><caption><p>Medial region cartilage volume at baseline according to median value of baseline biomarker levels. <bold>Table S2.</bold> Medial region cartilage volume at baseline according to median value of baseline biomarker levels per treatment group. (PDF 66 kb)</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>ANCOVA</term><def><p id="Par6">Analysis of covariance</p></def></def-item><def-item><term>ATP</term><def><p id="Par7">According-to-protocol</p></def></def-item><def-item><term>BMI</term><def><p id="Par8">Body mass index</p></def></def-item><def-item><term>CRP</term><def><p id="Par9">C reactive protein</p></def></def-item><def-item><term>CTX-1</term><def><p id="Par10">C-terminal crosslinked telopeptide of type I collagen</p></def></def-item><def-item><term>ELISA</term><def><p id="Par11">Enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>HA</term><def><p id="Par12">Hyaluronic acid</p></def></def-item><def-item><term>KL</term><def><p id="Par13">Kellgren-Lawrence</p></def></def-item><def-item><term>MDD</term><def><p id="Par14">Minimum detectable dose</p></def></def-item><def-item><term>MMP</term><def><p id="Par15">Matrix metalloproteinase</p></def></def-item><def-item><term>NSAID</term><def><p id="Par16">Non-steroidal anti-inflammatory drug</p></def></def-item><def-item><term>OA</term><def><p id="Par17">Osteoarthritis</p></def></def-item><def-item><term>PIIANP</term><def><p id="Par18">N-terminal propeptide of collagen II&#x003b1;</p></def></def-item><def-item><term>qMRI</term><def><p id="Par19">Quantitative magnetic resonance imaging</p></def></def-item><def-item><term>SD</term><def><p id="Par20">Standard deviation</p></def></def-item><def-item><term>VAS</term><def><p id="Par21">Visual analog scale</p></def></def-item><def-item><term>WOMAC</term><def><p id="Par22">Western Ontario and McMaster Universities Osteoarthritis Index</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1186/s13075-017-1377-y) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors thank Andr&#x000e9; Pelletier and Jos&#x000e9;e Th&#x000e9;riault for the MRI reading and Virginia Wallis for her assistance with the manuscript preparation.</p><sec id="FPar1"><title>Funding</title><p id="Par63">The original trial was funded by Bioib&#x000e9;rica SAU, Barcelona, Spain. The sponsor provided all of the study medication free of charge and met the expenses that arose during the course of the study and post hoc analysis. This study was funded by an unrestrictive grant from Bioib&#x000e9;rica. The sponsor had no role in the design or conduct of the study, the management, analysis, or interpretation of the data, or the preparation, review, or approval of the manuscript. The sponsor had no access to the data and did not perform any of the study analysis.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>JM-P and J-PP designed the study and J-PR participated in the study design. PP was responsible for the collection and integrity of the serum. FM conducted the biomarker experiments and the related data interpretation. FA performed the MRI determination and the related data interpretation. PD performed the statistical analyses and related data interpretation. JM-P, J-PP, J-PR, and PD performed the overall data analysis and interpretation. JM-P and J-PP drafted the manuscript and J-PR assisted with drafting the manuscript. All of the authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par65">The original study protocol was approved by a central review board (IRB Institutional Review Board Services, Toronto, ON, Canada) and the institutional review board of the Centre hospitalier de l&#x02019;Universit&#x000e9; de Sherbrooke (CHUS), Sherbrooke, QC, Canada. The original trial [<xref ref-type="bibr" rid="CR6">6</xref>] was conducted in compliance with the ethical principles that have their origin in the Declaration of Helsinki (2000) and are consistent with the &#x0201c;Good Clinical Practice&#x0201d; ICH Tripartite Guideline (January 1997) and the applicable laws and regulations of Canada, whichever afforded the greater protection to the individual. Ethical approval for this post hoc study was obtained with the original study, thus further approval was not required. All patients provided informed consent.</p></sec><sec id="FPar4"><title>Competing interests</title><p id="Par66">JM-P and J-PP are consultants for Bioiberica, SAU and shareholders in ArthroLab Inc. J-PR is a consultant for ArthroLab Inc. FA, PP and PD are employees of ArthroLab Inc. FM has no conflict of interest. No non-financial conflicts of interest exist for any of the authors.</p></sec><sec id="FPar5"><title>Publisher&#x02019;s Note</title><p id="Par67">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>PS</given-names></name><name><surname>Caron</surname><given-names>JP</given-names></name><name><surname>Orth</surname><given-names>MW</given-names></name></person-group><article-title>Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants</article-title><source>Am J Vet Res</source><year>2005</year><volume>66</volume><issue>11</issue><fpage>1870</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.2460/ajvr.2005.66.1870</pub-id><pub-id pub-id-type="pmid">16334942</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tat</surname><given-names>SK</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name><name><surname>Verg&#x000e9;s</surname><given-names>J</given-names></name><name><surname>Montell</surname><given-names>E</given-names></name><name><surname>Lajeunesse</surname><given-names>D</given-names></name><name><surname>Fahmi</surname><given-names>H</given-names></name><name><surname>Lavigne</surname><given-names>M</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name></person-group><article-title>Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts</article-title><source>Arthritis Res Ther</source><year>2007</year><volume>9</volume><fpage>R117</fpage><pub-id pub-id-type="doi">10.1186/ar2325</pub-id><pub-id pub-id-type="pmid">17996099</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monfort</surname><given-names>J</given-names></name><name><surname>Pelletier</surname><given-names>J-P</given-names></name><name><surname>Garcia-Giralt</surname><given-names>N</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name></person-group><article-title>Biochemical basis of the effect of chondroitin sulfate on osteoarthritis articular tissues</article-title><source>Ann Rheum Dis</source><year>2008</year><volume>67</volume><fpage>735</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1136/ard.2006.068882</pub-id><pub-id pub-id-type="pmid">17644553</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>du Souich</surname><given-names>P</given-names></name><name><surname>Garcia</surname><given-names>AG</given-names></name><name><surname>Verges</surname><given-names>J</given-names></name><name><surname>Montell</surname><given-names>E</given-names></name></person-group><article-title>Immunomodulatory and anti-inflammatory effects of chondroitin sulphate</article-title><source>J Cell Mol Med</source><year>2009</year><volume>13</volume><issue>8A</issue><fpage>1451</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2009.00826.x</pub-id><pub-id pub-id-type="pmid">19522843</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Kwan Tat</surname><given-names>S</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name></person-group><article-title>Effects of chondroitin sulfate in the pathophysiology of the osteoarthritic joint: a narrative review</article-title><source>Osteoarthritis Cartilage</source><year>2010</year><volume>18</volume><issue>Suppl 1</issue><fpage>S7</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2010.01.015</pub-id><pub-id pub-id-type="pmid">20399897</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>JP</given-names></name><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Beaulieu</surname><given-names>AD</given-names></name><name><surname>Bessette</surname><given-names>L</given-names></name><name><surname>Morin</surname><given-names>F</given-names></name><name><surname>de Brum-Fernandes</surname><given-names>AJ</given-names></name><name><surname>Delorme</surname><given-names>P</given-names></name><name><surname>Dorais</surname><given-names>M</given-names></name><name><surname>Paiement</surname><given-names>P</given-names></name><name><surname>Abram</surname><given-names>F</given-names></name><etal/></person-group><article-title>Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study</article-title><source>Arthritis Res Ther</source><year>2016</year><volume>18</volume><issue>1</issue><fpage>256</fpage><pub-id pub-id-type="doi">10.1186/s13075-016-1149-0</pub-id><pub-id pub-id-type="pmid">27809891</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Monfort</surname><given-names>J</given-names></name><name><surname>Moller</surname><given-names>I</given-names></name><name><surname>Castillo</surname><given-names>JR</given-names></name><name><surname>Arden</surname><given-names>N</given-names></name><name><surname>Berenbaum</surname><given-names>F</given-names></name><name><surname>Blanco</surname><given-names>FJ</given-names></name><name><surname>Conaghan</surname><given-names>PG</given-names></name><name><surname>Domenech</surname><given-names>G</given-names></name><etal/></person-group><article-title>Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib</article-title><source>Ann Rheum Dis</source><year>2016</year><volume>75</volume><issue>1</issue><fpage>37</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2014-206792</pub-id><pub-id pub-id-type="pmid">25589511</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wildi</surname><given-names>LM</given-names></name><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Beaulieu</surname><given-names>A</given-names></name><name><surname>Bessette</surname><given-names>L</given-names></name><name><surname>Morin</surname><given-names>F</given-names></name><name><surname>Abram</surname><given-names>F</given-names></name><name><surname>Dorais</surname><given-names>M</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name></person-group><article-title>Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6&#x000a0;months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI</article-title><source>Ann Rheum Dis</source><year>2011</year><volume>70</volume><issue>6</issue><fpage>982</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1136/ard.2010.140848</pub-id><pub-id pub-id-type="pmid">21367761</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Roubille</surname><given-names>C</given-names></name><name><surname>Abram</surname><given-names>F</given-names></name><name><surname>Hochberg</surname><given-names>MC</given-names></name><name><surname>Dorais</surname><given-names>M</given-names></name><name><surname>Delorme</surname><given-names>P</given-names></name><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name></person-group><article-title>First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24&#x000a0;months: data from the osteoarthritis initiative progression cohort</article-title><source>Ann Rheum Dis</source><year>2015</year><volume>74</volume><issue>3</issue><fpage>547</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2013-203906</pub-id><pub-id pub-id-type="pmid">24336337</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>KM</given-names></name><name><surname>Arden</surname><given-names>NK</given-names></name><name><surname>Doherty</surname><given-names>M</given-names></name><name><surname>Bannwarth</surname><given-names>B</given-names></name><name><surname>Bijlsma</surname><given-names>JW</given-names></name><name><surname>Dieppe</surname><given-names>P</given-names></name><name><surname>Gunther</surname><given-names>K</given-names></name><name><surname>Hauselmann</surname><given-names>H</given-names></name><name><surname>Herrero-Beaumont</surname><given-names>G</given-names></name><name><surname>Kaklamanis</surname><given-names>P</given-names></name><etal/></person-group><article-title>EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)</article-title><source>Ann Rheum Dis</source><year>2003</year><volume>62</volume><issue>12</issue><fpage>1145</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1136/ard.2003.011742</pub-id><pub-id pub-id-type="pmid">14644851</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruyere</surname><given-names>O</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name><name><surname>Branco</surname><given-names>J</given-names></name><name><surname>Luisa Brandi</surname><given-names>M</given-names></name><name><surname>Guillemin</surname><given-names>F</given-names></name><name><surname>Hochberg</surname><given-names>MC</given-names></name><name><surname>Kanis</surname><given-names>JA</given-names></name><name><surname>Kvien</surname><given-names>TK</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><etal/></person-group><article-title>An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)</article-title><source>Semin Arthritis Rheum</source><year>2014</year><volume>44</volume><issue>3</issue><fpage>253</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.semarthrit.2014.05.014</pub-id><pub-id pub-id-type="pmid">24953861</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name><name><surname>Altman</surname><given-names>RD</given-names></name><name><surname>April</surname><given-names>KT</given-names></name><name><surname>Benkhalti</surname><given-names>M</given-names></name><name><surname>Guyatt</surname><given-names>G</given-names></name><name><surname>McGowan</surname><given-names>J</given-names></name><name><surname>Towheed</surname><given-names>T</given-names></name><name><surname>Welch</surname><given-names>V</given-names></name><name><surname>Wells</surname><given-names>G</given-names></name><name><surname>Tugwell</surname><given-names>P</given-names></name></person-group><article-title>American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee</article-title><source>Arthritis Care Res (Hoboken)</source><year>2012</year><volume>64</volume><issue>4</issue><fpage>465</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1002/acr.21596</pub-id><pub-id pub-id-type="pmid">22563589</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAlindon</surname><given-names>TE</given-names></name><name><surname>Bannuru</surname><given-names>RR</given-names></name><name><surname>Sullivan</surname><given-names>MC</given-names></name><name><surname>Arden</surname><given-names>NK</given-names></name><name><surname>Berenbaum</surname><given-names>F</given-names></name><name><surname>Bierma-Zeinstra</surname><given-names>SM</given-names></name><name><surname>Hawker</surname><given-names>GA</given-names></name><name><surname>Henrotin</surname><given-names>Y</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Kawaguchi</surname><given-names>H</given-names></name><etal/></person-group><article-title>OARSI guidelines for the non-surgical management of knee osteoarthritis</article-title><source>Osteoarthritis Cartilage</source><year>2014</year><volume>22</volume><issue>3</issue><fpage>363</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2014.01.003</pub-id><pub-id pub-id-type="pmid">24462672</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lotz</surname><given-names>M</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Christiansen</surname><given-names>C</given-names></name><name><surname>Brandi</surname><given-names>ML</given-names></name><name><surname>Bruyere</surname><given-names>O</given-names></name><name><surname>Chapurlat</surname><given-names>R</given-names></name><name><surname>Collette</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Giacovelli</surname><given-names>G</given-names></name><name><surname>Kanis</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Value of biomarkers in osteoarthritis: current status and perspectives</article-title><source>Ann Rheum Dis</source><year>2013</year><volume>72</volume><issue>11</issue><fpage>1756</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2013-203726</pub-id><pub-id pub-id-type="pmid">23897772</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daghestani</surname><given-names>HN</given-names></name><name><surname>Kraus</surname><given-names>VB</given-names></name></person-group><article-title>Inflammatory biomarkers in osteoarthritis</article-title><source>Osteoarthritis Cartilage</source><year>2015</year><volume>23</volume><issue>11</issue><fpage>1890</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2015.02.009</pub-id><pub-id pub-id-type="pmid">26521734</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Nevitt</surname><given-names>M</given-names></name><name><surname>Losina</surname><given-names>E</given-names></name><name><surname>Kraus</surname><given-names>V</given-names></name></person-group><article-title>Biomarkers for osteoarthritis: current position and steps towards further validation</article-title><source>Best Pract Res Clin Rheumatol</source><year>2014</year><volume>28</volume><issue>1</issue><fpage>61</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.berh.2014.01.007</pub-id><pub-id pub-id-type="pmid">24792945</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraus</surname><given-names>VB</given-names></name><name><surname>Blanco</surname><given-names>FJ</given-names></name><name><surname>Englund</surname><given-names>M</given-names></name><name><surname>Henrotin</surname><given-names>Y</given-names></name><name><surname>Lohmander</surname><given-names>LS</given-names></name><name><surname>Losina</surname><given-names>E</given-names></name><name><surname>Onnerfjord</surname><given-names>P</given-names></name><name><surname>Persiani</surname><given-names>S</given-names></name></person-group><article-title>OARSI clinical trials recommendations: soluble biomarker assessments in clinical trials in osteoarthritis</article-title><source>Osteoarthritis Cartilage</source><year>2015</year><volume>23</volume><issue>5</issue><fpage>686</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2015.03.002</pub-id><pub-id pub-id-type="pmid">25952342</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraus</surname><given-names>VB</given-names></name><name><surname>Collins</surname><given-names>JE</given-names></name><name><surname>Hargrove</surname><given-names>D</given-names></name><name><surname>Losina</surname><given-names>E</given-names></name><name><surname>Nevitt</surname><given-names>M</given-names></name><name><surname>Katz</surname><given-names>JN</given-names></name><name><surname>Wang</surname><given-names>SX</given-names></name><name><surname>Sandell</surname><given-names>LJ</given-names></name><name><surname>Hoffmann</surname><given-names>SC</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers Consortium</article-title><source>Ann Rheum Dis</source><year>2016</year></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arden</surname><given-names>N</given-names></name><name><surname>Richette</surname><given-names>P</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Bruyere</surname><given-names>O</given-names></name><name><surname>Abadie</surname><given-names>E</given-names></name><name><surname>Branco</surname><given-names>J</given-names></name><name><surname>Brandi</surname><given-names>ML</given-names></name><name><surname>Berenbaum</surname><given-names>F</given-names></name><name><surname>Clerc</surname><given-names>C</given-names></name><name><surname>Dennison</surname><given-names>E</given-names></name><etal/></person-group><article-title>Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on biomarkers and frailty</article-title><source>Drugs Aging</source><year>2015</year><volume>32</volume><issue>7</issue><fpage>525</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1007/s40266-015-0276-7</pub-id><pub-id pub-id-type="pmid">26085027</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attur</surname><given-names>M</given-names></name><name><surname>Krasnokutsky-Samuels</surname><given-names>S</given-names></name><name><surname>Samuels</surname><given-names>J</given-names></name><name><surname>Abramson</surname><given-names>SB</given-names></name></person-group><article-title>Prognostic biomarkers in osteoarthritis</article-title><source>Curr Opin Rheumatol</source><year>2013</year><volume>25</volume><issue>1</issue><fpage>136</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1097/BOR.0b013e32835a9381</pub-id><pub-id pub-id-type="pmid">23169101</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraus</surname><given-names>VB</given-names></name><name><surname>Hargrove</surname><given-names>DE</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Renner</surname><given-names>JB</given-names></name><name><surname>Jordan</surname><given-names>JM</given-names></name></person-group><article-title>Establishment of reference intervals for osteoarthritis-related soluble biomarkers: the FNIH/OARSI OA Biomarkers Consortium</article-title><source>Ann Rheum Dis</source><year>2016</year></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>JP</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Peterfy</surname><given-names>C</given-names></name><name><surname>Reginster</surname><given-names>JY</given-names></name><name><surname>Brandi</surname><given-names>ML</given-names></name><name><surname>Bruyere</surname><given-names>O</given-names></name><name><surname>Chapurlat</surname><given-names>R</given-names></name><name><surname>Cicuttini</surname><given-names>F</given-names></name><name><surname>Conaghan</surname><given-names>PG</given-names></name><name><surname>Doherty</surname><given-names>M</given-names></name><etal/></person-group><article-title>What is the predictive value of MRI for the occurrence of knee replacement surgery in knee osteoarthritis?</article-title><source>Ann Rheum Dis</source><year>2013</year><volume>72</volume><issue>10</issue><fpage>1594</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2013-203631</pub-id><pub-id pub-id-type="pmid">23887285</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>JP</given-names></name><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Caron</surname><given-names>J</given-names></name><name><surname>Mineau</surname><given-names>F</given-names></name><name><surname>Abram</surname><given-names>F</given-names></name><name><surname>Dorais</surname><given-names>M</given-names></name><name><surname>Haraoui</surname><given-names>B</given-names></name><name><surname>Choquette</surname><given-names>D</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name></person-group><article-title>Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis</article-title><source>Ann Rheum Dis</source><year>2010</year><volume>69</volume><issue>12</issue><fpage>2095</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1136/ard.2009.122002</pub-id><pub-id pub-id-type="pmid">20570834</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Dorais</surname><given-names>M</given-names></name><name><surname>Abram</surname><given-names>F</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name></person-group><article-title>The levels of the adipokines adipsin and leptin are associated with knee osteoarthritis progression as assessed by MRI and incidence of total knee replacement in symptomatic osteoarthritis patients: a post hoc analysis</article-title><source>Rheumatology (Oxford)</source><year>2016</year><volume>55</volume><issue>4</issue><fpage>680</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/kev408</pub-id><pub-id pub-id-type="pmid">26660640</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altman</surname><given-names>R</given-names></name><name><surname>Asch</surname><given-names>E</given-names></name><name><surname>Bloch</surname><given-names>D</given-names></name><name><surname>Bole</surname><given-names>G</given-names></name><name><surname>Borenstein</surname><given-names>D</given-names></name><name><surname>Brandt</surname><given-names>K</given-names></name><name><surname>Christy</surname><given-names>W</given-names></name><name><surname>Cooke</surname><given-names>TD</given-names></name><name><surname>Greenwald</surname><given-names>R</given-names></name><name><surname>Hochberg</surname><given-names>M</given-names></name><etal/></person-group><article-title>Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association</article-title><source>Arthritis Rheum</source><year>1986</year><volume>29</volume><issue>8</issue><fpage>1039</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1002/art.1780290816</pub-id><pub-id pub-id-type="pmid">3741515</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Beaulieu</surname><given-names>A</given-names></name><name><surname>Bessette</surname><given-names>L</given-names></name><name><surname>Morin</surname><given-names>F</given-names></name><name><surname>Choquette</surname><given-names>D</given-names></name><name><surname>Haraoui</surname><given-names>B</given-names></name><name><surname>Abram</surname><given-names>F</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name></person-group><article-title>An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis</article-title><source>Semin Arthritis Rheum</source><year>2010</year><volume>40</volume><issue>3</issue><fpage>185</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.semarthrit.2009.10.003</pub-id><pub-id pub-id-type="pmid">20132966</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Berthiaume</surname><given-names>MJ</given-names></name><name><surname>Labont&#x000e9;</surname><given-names>F</given-names></name><name><surname>Beaudoin</surname><given-names>G</given-names></name><name><surname>de Guise</surname><given-names>JA</given-names></name><name><surname>Bloch</surname><given-names>DA</given-names></name><name><surname>Choquette</surname><given-names>D</given-names></name><name><surname>Haraoui</surname><given-names>B</given-names></name><name><surname>Altman</surname><given-names>RD</given-names></name><etal/></person-group><article-title>Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes</article-title><source>Arthritis Rheum</source><year>2004</year><volume>50</volume><fpage>476</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1002/art.20000</pub-id><pub-id pub-id-type="pmid">14872490</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kauffmann</surname><given-names>C</given-names></name><name><surname>Gravel</surname><given-names>P</given-names></name><name><surname>Godbout</surname><given-names>B</given-names></name><name><surname>Gravel</surname><given-names>A</given-names></name><name><surname>Beaudoin</surname><given-names>G</given-names></name><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name><name><surname>de Guise</surname><given-names>JA</given-names></name></person-group><article-title>Computer-aided method for quantification of cartilage thickness and volume changes using MRI: validation study using a synthetic model</article-title><source>IEEE Trans Biomed Eng</source><year>2003</year><volume>50</volume><issue>8</issue><fpage>978</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1109/TBME.2003.814539</pub-id><pub-id pub-id-type="pmid">12892325</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>JP</given-names></name><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Abram</surname><given-names>F</given-names></name><name><surname>Haraoui</surname><given-names>B</given-names></name><name><surname>Choquette</surname><given-names>D</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name></person-group><article-title>A new non-invasive method to assess synovitis severity in relation to symptoms and cartilage volume loss in knee osteoarthritis patients using MRI</article-title><source>Osteoarthritis Cartilage</source><year>2008</year><volume>16</volume><issue>Suppl 3</issue><fpage>S8</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2008.06.007</pub-id><pub-id pub-id-type="pmid">18672386</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Abram</surname><given-names>F</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Dorais</surname><given-names>M</given-names></name><name><surname>d&#x02019;Anjou</surname><given-names>MA</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name></person-group><article-title>Fully automated system for the quantification of human osteoarthritic knee joint effusion volume using magnetic resonance imaging</article-title><source>Arthritis Res Ther</source><year>2010</year><volume>12</volume><issue>5</issue><fpage>R173</fpage><pub-id pub-id-type="doi">10.1186/ar3133</pub-id><pub-id pub-id-type="pmid">20846392</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Berthiaume</surname><given-names>MJ</given-names></name><name><surname>Beaudoin</surname><given-names>G</given-names></name><name><surname>Choquette</surname><given-names>D</given-names></name><name><surname>Haraoui</surname><given-names>B</given-names></name><name><surname>Tannenbaum</surname><given-names>H</given-names></name><name><surname>Meyer</surname><given-names>JM</given-names></name><name><surname>Beary</surname><given-names>JF</given-names></name><name><surname>Cline</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes</article-title><source>Arthritis Res Ther</source><year>2006</year><volume>8</volume><issue>1</issue><fpage>R21</fpage><pub-id pub-id-type="doi">10.1186/ar1875</pub-id><pub-id pub-id-type="pmid">16507119</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wildi</surname><given-names>LM</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Abram</surname><given-names>F</given-names></name><name><surname>Moser</surname><given-names>T</given-names></name><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name></person-group><article-title>Assessment of cartilage changes over time in knee osteoarthritis disease-modifying osteoarthritis drug trials using semiquantitative and quantitative methods: pros and cons</article-title><source>Arthritis Care Res (Hoboken)</source><year>2013</year><volume>65</volume><issue>5</issue><fpage>686</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1002/acr.21890</pub-id><pub-id pub-id-type="pmid">23139244</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koskinen</surname><given-names>A</given-names></name><name><surname>Vuolteenaho</surname><given-names>K</given-names></name><name><surname>Nieminen</surname><given-names>R</given-names></name><name><surname>Moilanen</surname><given-names>T</given-names></name><name><surname>Moilanen</surname><given-names>E</given-names></name></person-group><article-title>Leptin enhances MMP-1, MMP-3 and MMP-13 production in human osteoarthritic cartilage and correlates with MMP-1 and MMP-3 in synovial fluid from OA patients</article-title><source>Clin Exp Rheumatol</source><year>2011</year><volume>29</volume><issue>1</issue><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">21345293</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bay-Jensen</surname><given-names>AC</given-names></name><name><surname>Reker</surname><given-names>D</given-names></name><name><surname>Kjelgaard-Petersen</surname><given-names>CF</given-names></name><name><surname>Mobasheri</surname><given-names>A</given-names></name><name><surname>Karsdal</surname><given-names>MA</given-names></name><name><surname>Ladel</surname><given-names>C</given-names></name><name><surname>Henrotin</surname><given-names>Y</given-names></name><name><surname>Thudium</surname><given-names>CS</given-names></name></person-group><article-title>Osteoarthritis year in review 2015: soluble biomarkers and the BIPED criteria</article-title><source>Osteoarthritis Cartilage</source><year>2016</year><volume>24</volume><issue>1</issue><fpage>9</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2015.10.014</pub-id><pub-id pub-id-type="pmid">26707988</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>JW</given-names></name><name><surname>Martins</surname><given-names>TB</given-names></name><name><surname>Gopez</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>T</given-names></name><name><surname>Hill</surname><given-names>HR</given-names></name><name><surname>Rosenberg</surname><given-names>TD</given-names></name></person-group><article-title>Significance of C-reactive protein in osteoarthritis and total knee arthroplasty outcomes</article-title><source>Ther Adv Musculoskelet Dis</source><year>2012</year><volume>4</volume><issue>5</issue><fpage>315</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1177/1759720X12455959</pub-id><pub-id pub-id-type="pmid">23024709</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharif</surname><given-names>M</given-names></name><name><surname>Shepstone</surname><given-names>L</given-names></name><name><surname>Elson</surname><given-names>CJ</given-names></name><name><surname>Dieppe</surname><given-names>PA</given-names></name><name><surname>Kirwan</surname><given-names>JR</given-names></name></person-group><article-title>Increased serum C reactive protein may reflect events that precede radiographic progression in osteoarthritis of the knee</article-title><source>Ann Rheum Dis</source><year>2000</year><volume>59</volume><fpage>71</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1136/ard.59.1.71</pub-id><pub-id pub-id-type="pmid">10627432</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Hunter</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name></person-group><article-title>Metabolic triggered inflammation in osteoarthritis</article-title><source>Osteoarthritis Cartilage</source><year>2015</year><volume>23</volume><issue>1</issue><fpage>22</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2014.10.002</pub-id><pub-id pub-id-type="pmid">25452156</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saberi Hosnijeh</surname><given-names>F</given-names></name><name><surname>Siebuhr</surname><given-names>AS</given-names></name><name><surname>Uitterlinden</surname><given-names>AG</given-names></name><name><surname>Oei</surname><given-names>EH</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Karsdal</surname><given-names>MA</given-names></name><name><surname>Bierma-Zeinstra</surname><given-names>SM</given-names></name><name><surname>Bay-Jensen</surname><given-names>AC</given-names></name><name><surname>van Meurs</surname><given-names>JB</given-names></name></person-group><article-title>Association between biomarkers of tissue inflammation and progression of osteoarthritis: evidence from the Rotterdam study cohort</article-title><source>Arthritis Res Ther</source><year>2015</year><volume>18</volume><fpage>81</fpage><pub-id pub-id-type="doi">10.1186/s13075-016-0976-3</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Beguerie</surname><given-names>JR</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Blizzard</surname><given-names>L</given-names></name><name><surname>Otahal</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>G</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name></person-group><article-title>Circulating C reactive protein in osteoarthritis: a systematic review and meta-analysis</article-title><source>Ann Rheum Dis</source><year>2015</year><volume>74</volume><issue>4</issue><fpage>703</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2013-204494</pub-id><pub-id pub-id-type="pmid">24363360</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roubille</surname><given-names>C</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Abram</surname><given-names>F</given-names></name><name><surname>Dorais</surname><given-names>M</given-names></name><name><surname>Delorme</surname><given-names>P</given-names></name><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name></person-group><article-title>Impact of disease treatments on the progression of knee osteoarthritis structural changes related to meniscal extrusion: Data from the OAI progression cohort</article-title><source>Semin Arthritis Rheum</source><year>2015</year><volume>45</volume><issue>3</issue><fpage>257</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.semarthrit.2015.05.001</pub-id><pub-id pub-id-type="pmid">26094904</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Sharma</surname><given-names>NR</given-names></name></person-group><article-title>Role of hyaluronic acid in early diagnosis of knee osteoarthritis</article-title><source>J Clin Diagn Res</source><year>2014</year><volume>8</volume><issue>12</issue><fpage>LC04</fpage><lpage>07</lpage><pub-id pub-id-type="pmid">25653977</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Boer</surname><given-names>TN</given-names></name><name><surname>van Spil</surname><given-names>WE</given-names></name><name><surname>Huisman</surname><given-names>AM</given-names></name><name><surname>Polak</surname><given-names>AA</given-names></name><name><surname>Bijlsma</surname><given-names>JW</given-names></name><name><surname>Lafeber</surname><given-names>FP</given-names></name><name><surname>Mastbergen</surname><given-names>SC</given-names></name></person-group><article-title>Serum adipokines in osteoarthritis; comparison with controls and relationship with local parameters of synovial inflammation and cartilage damage</article-title><source>Osteoarthritis Cartilage</source><year>2012</year><volume>20</volume><issue>8</issue><fpage>846</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2012.05.002</pub-id><pub-id pub-id-type="pmid">22595228</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stannus</surname><given-names>OP</given-names></name><name><surname>Jones</surname><given-names>G</given-names></name><name><surname>Quinn</surname><given-names>SJ</given-names></name><name><surname>Cicuttini</surname><given-names>FM</given-names></name><name><surname>Dore</surname><given-names>D</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name></person-group><article-title>The association between leptin, interleukin-6, and hip radiographic osteoarthritis in older people: a cross-sectional study</article-title><source>Arthritis Res Ther</source><year>2010</year><volume>12</volume><issue>3</issue><fpage>R95</fpage><pub-id pub-id-type="doi">10.1186/ar3022</pub-id><pub-id pub-id-type="pmid">20482813</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stannus</surname><given-names>OP</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Antony</surname><given-names>B</given-names></name><name><surname>Blizzard</surname><given-names>L</given-names></name><name><surname>Cicuttini</surname><given-names>F</given-names></name><name><surname>Jones</surname><given-names>G</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name></person-group><article-title>Cross-sectional and longitudinal associations between circulating leptin and knee cartilage thickness in older adults</article-title><source>Ann Rheum Dis</source><year>2015</year><volume>74</volume><issue>1</issue><fpage>82</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2013-203308</pub-id><pub-id pub-id-type="pmid">24078677</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>PA</given-names></name><name><surname>Maciewicz</surname><given-names>RA</given-names></name><name><surname>Wluka</surname><given-names>AE</given-names></name><name><surname>Downey-Jones</surname><given-names>MD</given-names></name><name><surname>Forbes</surname><given-names>A</given-names></name><name><surname>Hellawell</surname><given-names>CJ</given-names></name><name><surname>Cicuttini</surname><given-names>FM</given-names></name></person-group><article-title>Relationship of serum markers of cartilage metabolism to imaging and clinical outcome measures of knee joint structure</article-title><source>Ann Rheum Dis</source><year>2010</year><volume>69</volume><issue>10</issue><fpage>1816</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1136/ard.2009.124420</pub-id><pub-id pub-id-type="pmid">20551154</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Raynauld JP, Pelletier JP, Delorme P, Dodin P, Abram F, Martel-Pelletier J. Bone curvature changes can predict in knee osteoarthritis the impact of treatment on cartilage volume loss: data from a two-year clinical trial. Rheumatology (Oxford). 2017;56(6):989-98.</mixed-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uebelhart</surname><given-names>D</given-names></name><name><surname>Malaise</surname><given-names>M</given-names></name><name><surname>Marcolongo</surname><given-names>R</given-names></name><name><surname>DeVathaire</surname><given-names>F</given-names></name><name><surname>Piperno</surname><given-names>M</given-names></name><name><surname>Mailleux</surname><given-names>E</given-names></name><name><surname>Fioravanti</surname><given-names>A</given-names></name><name><surname>Matoso</surname><given-names>L</given-names></name><name><surname>Vignon</surname><given-names>E</given-names></name></person-group><article-title>Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo</article-title><source>Osteoarthritis Cartilage</source><year>2004</year><volume>12</volume><issue>4</issue><fpage>269</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2004.01.004</pub-id><pub-id pub-id-type="pmid">15023378</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michel</surname><given-names>BA</given-names></name><name><surname>Stucki</surname><given-names>G</given-names></name><name><surname>Frey</surname><given-names>D</given-names></name><name><surname>De Vathaire</surname><given-names>F</given-names></name><name><surname>Vignon</surname><given-names>E</given-names></name><name><surname>Bruehlmann</surname><given-names>P</given-names></name><name><surname>Uebelhart</surname><given-names>D</given-names></name></person-group><article-title>Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial</article-title><source>Arthritis Rheum</source><year>2005</year><volume>52</volume><issue>3</issue><fpage>779</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1002/art.20867</pub-id><pub-id pub-id-type="pmid">15751094</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahan</surname><given-names>A</given-names></name><name><surname>Uebelhart</surname><given-names>D</given-names></name><name><surname>De Vathaire</surname><given-names>F</given-names></name><name><surname>Delmas</surname><given-names>PD</given-names></name><name><surname>Reginster</surname><given-names>JY</given-names></name></person-group><article-title>Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial</article-title><source>Arthritis Rheum</source><year>2009</year><volume>60</volume><issue>2</issue><fpage>524</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1002/art.24255</pub-id><pub-id pub-id-type="pmid">19180484</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group><article-title>Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration</article-title><source>Osteoarthritis Cartilage</source><year>2010</year><volume>18</volume><issue>Suppl 1</issue><fpage>S28</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2010.02.016</pub-id><pub-id pub-id-type="pmid">20399895</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Woo</surname><given-names>JH</given-names></name><name><surname>Choi</surname><given-names>SJ</given-names></name><name><surname>Ji</surname><given-names>JD</given-names></name><name><surname>Song</surname><given-names>GG</given-names></name></person-group><article-title>Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis</article-title><source>Rheumatol Int</source><year>2010</year><volume>30</volume><issue>3</issue><fpage>357</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1007/s00296-009-0969-5</pub-id><pub-id pub-id-type="pmid">19544061</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>M</given-names></name><name><surname>Chevalier</surname><given-names>X</given-names></name><name><surname>Henrotin</surname><given-names>Y</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Uebelhart</surname><given-names>D</given-names></name></person-group><article-title>Symptom and structure modification in osteoarthritis with pharmaceutical-grade chondroitin sulfate: what&#x02019;s the evidence?</article-title><source>Curr Med Res Opin</source><year>2013</year><volume>29</volume><issue>3</issue><fpage>259</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1185/03007995.2012.753430</pub-id><pub-id pub-id-type="pmid">23186102</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>B</given-names></name><name><surname>Tjoumakaris</surname><given-names>FP</given-names></name><name><surname>Harwood</surname><given-names>MI</given-names></name><name><surname>Good</surname><given-names>RP</given-names></name><name><surname>Ciccotti</surname><given-names>MG</given-names></name><name><surname>Freedman</surname><given-names>KB</given-names></name></person-group><article-title>Chondroprotection and the prevention of osteoarthritis progression of the knee: a systematic review of treatment agents</article-title><source>Am J Sports Med</source><year>2015</year><volume>43</volume><issue>3</issue><fpage>734</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1177/0363546514533777</pub-id><pub-id pub-id-type="pmid">24866892</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>JA</given-names></name><name><surname>Noorbaloochi</surname><given-names>S</given-names></name><name><surname>MacDonald</surname><given-names>R</given-names></name><name><surname>Maxwell</surname><given-names>LJ</given-names></name></person-group><article-title>Chondroitin for osteoarthritis</article-title><source>Cochrane Database Syst Rev</source><year>2015</year><volume>1</volume><fpage>CD005614</fpage><pub-id pub-id-type="pmid">25629804</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richy</surname><given-names>F</given-names></name><name><surname>Bruyere</surname><given-names>O</given-names></name><name><surname>Ethgen</surname><given-names>O</given-names></name><name><surname>Cucherat</surname><given-names>M</given-names></name><name><surname>Henrotin</surname><given-names>Y</given-names></name><name><surname>Reginster</surname><given-names>JY</given-names></name></person-group><article-title>Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis</article-title><source>Arch Intern Med</source><year>2003</year><volume>163</volume><issue>13</issue><fpage>1514</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1001/archinte.163.13.1514</pub-id><pub-id pub-id-type="pmid">12860572</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clegg</surname><given-names>DO</given-names></name><name><surname>Reda</surname><given-names>DJ</given-names></name><name><surname>Harris</surname><given-names>CL</given-names></name><name><surname>Klein</surname><given-names>MA</given-names></name><name><surname>O&#x02019;Dell</surname><given-names>JR</given-names></name><name><surname>Hooper</surname><given-names>MM</given-names></name><name><surname>Bradley</surname><given-names>JD</given-names></name><name><surname>Bingham</surname><given-names>CO</given-names><suffix>3rd</suffix></name><name><surname>Weisman</surname><given-names>MH</given-names></name><name><surname>Jackson</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><issue>8</issue><fpage>795</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa052771</pub-id><pub-id pub-id-type="pmid">16495392</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichenbach</surname><given-names>S</given-names></name><name><surname>Sterchi</surname><given-names>R</given-names></name><name><surname>Scherer</surname><given-names>M</given-names></name><name><surname>Trelle</surname><given-names>S</given-names></name><name><surname>Burgi</surname><given-names>E</given-names></name><name><surname>Burgi</surname><given-names>U</given-names></name><name><surname>Dieppe</surname><given-names>PA</given-names></name><name><surname>Juni</surname><given-names>P</given-names></name></person-group><article-title>Meta-analysis: chondroitin for osteoarthritis of the knee or hip</article-title><source>Ann Intern Med</source><year>2007</year><volume>146</volume><issue>8</issue><fpage>580</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-146-8-200704170-00009</pub-id><pub-id pub-id-type="pmid">17438317</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wandel</surname><given-names>S</given-names></name><name><surname>Juni</surname><given-names>P</given-names></name><name><surname>Tendal</surname><given-names>B</given-names></name><name><surname>Nuesch</surname><given-names>E</given-names></name><name><surname>Villiger</surname><given-names>PM</given-names></name><name><surname>Welton</surname><given-names>NJ</given-names></name><name><surname>Reichenbach</surname><given-names>S</given-names></name><name><surname>Trelle</surname><given-names>S</given-names></name></person-group><article-title>Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis</article-title><source>BMJ</source><year>2010</year><volume>341</volume><fpage>c4675</fpage><pub-id pub-id-type="doi">10.1136/bmj.c4675</pub-id><pub-id pub-id-type="pmid">20847017</pub-id></element-citation></ref></ref-list></back></article>